Canada: The Quebec Court Of Appeal Renders A Landmark Decision Regarding Prescription Drug Manufacturers' Duty To Warn

In a judgment rendered on May 8, 2019, the Quebec Court of Appeal1 upheld a Superior Court decision2 dismissing a class action in which the plaintiffs alleged that a manufacturer failed to provide sufficient information as to the risks of a prescription drug. This was the first time that the Court of Appeal considered the merits of a class action regarding a drug manufacturer's duty to warn.

This action was based on the manufacturer's liability for safety defects under section 1468, 1469 and 1473 of the Civil Code of Québec ("C.C.Q.") and the manufacturer's liability for safety defects under section 53 of the Consumer Protection Act ("C.P.A.").

In its judgment, the Court of Appeal set out a number of important rules of general application:

  1. The sale of prescription drugs by a pharmacist is not a consumer contract and therefore falls outside the scope of the C.P.A.[3]
  2. The doctrine of the learned intermediary applies with respect to the sale of prescription drugs. The manufacturer can therefore fulfill its duty to warn by adequately informing health care professionals.4
  3. While not determinative, compliance with regulatory standards tends to indicate that the manufacturer has fulfilled its obligation to provide the required information.5

In addition, the Court clarified the intensity of a drug manufacturer's obligation to inform of side effects observed in conjunction with the intake of a drug when there is no evidence that the drug itself can cause these effects.

Summary of the Facts:

Biaxin is an antibiotic which has been prescribed for more than 20 years to treat certain bacterial respiratory infections (for example pneumonia, bronchitis or pharyngitis) or cutaneous infections. This antibiotic is only available on prescription from a licensed physician. At all relevant times, various forms of neuropsychiatric side effects were disclosed in the "side effects" section of the Product Monograph (which has been updated on several occasions as possible side effects were reported during the post marketing surveillance of the drug).

At trial, some class members testified that they suffered from neuropsychiatric-related disorders concurrently while taking Biaxin. The plaintiffs alleged that these neuropsychiatric disorders had been caused by the drug. They argued that these risks should have been disclosed in the warning and precaution section of the Biaxin Product Monograph.

Court of Appeal Decision:

The Sale of Prescription Drugs by a Pharmacist Falls Outside the Scope of the C.P.A.

The Court of Appeal concluded that the sale of prescription drugs does not fall within the scope of the C.P.A.6 The act applies only to contracts between a consumer and a merchant in the course of its business.7 The Court noted that a pharmacist may, depending on the circumstances, engage in both professional or commercial activities.8 The sale of prescription drugs, however, necessarily involves the professional judgment of a physician or pharmacist when he or she advises the patient on the appropriate use of the drug.9 In this context, health professionals do not act as merchants within the meaning of the C.P.A.[10]

Further, the Court of Appeal found that the application of the C.P.A. would be inconsistent with the realities of drug development and marketing.11 Indeed, unlike the rules applicable under the C.C.Q., the C.P.A. does not contain an exemption of liability based on the state of knowledge at the time when the drug was made available on the market. Knowledge of the risks of a medication is acquired through its usage in a large population and based on the evolution of scientific and medical knowledge.12 The Court held that an exemption is needed to allow for the proper development and innovation in this industry.

Accordingly, the Court of Appeal found that the legislature could not have intended to apply the C.P.A. regime to this industry.

The Duty to Inform Users About the Risks of a Prescription Drug

A manufacturer must inform its users of the risks and dangers of its product and the means to avoid them. In order to establish a manufacturer's liability, the plaintiff will have to show: (1) that the product has a safety defect; (2) that the plaintiff suffered damage; and (3) that there is a causal link between the defect and the damage suffered.13

To demonstrate causation, the plaintiff will have to prove the materialization of the risk of a particular side effect of the drug.14 However, even without the evidence that the drug can cause the particular side effect, the mere fact that a serious side effect occurred concurrently with the intake of the drug may establish the existence of a possible risk which must be disclosed by the manufacturer.15

As stated above, the manufacturer will not be found liable if the causal relationship between the risk and the drug could not be known based on the state of knowledge at the time the drug was made available on the market. According to the Court of Appeal, this exemption aims to share the risks associated with technological and medical innovation between manufacturers and users.

The Learned Intermediary Rule

As a general rule, to fulfill its duty to warn, the manufacturer must directly inform the users. However, the Court recognized that the doctrine of the learned intermediary finds application in Quebec civil law in the context of the sale of prescription drugs. Thus, the manufacturer fulfills its obligation if it properly warns the competent intermediary such as the doctor and the pharmacist involved in prescribing and distributing the drug to the users.16

The Impact of Regulatory Compliance on a Manufacturer's Liability

Drug manufacturers are highly regulated and the development and approval of a new drug is overseen by Health Canada. 17 These rules also include a duty to continuously update the information disclosed to health professionals and users through the Product Monograph. They also specify the type of information that must be disclosed in the different categories and sub-categories of the Monograph.

In light of this context, the Court of Appeal stated that, while not determinative, compliance with such regulatory standards tends to indicate that the manufacturer has fulfilled its obligation to provide adequate information. Thus, it is an important factor to consider when assessing the diligence of a pharmaceutical manufacturer regarding its duty to inform.18

Conclusions of the Court of Appeal in this Case

Like the trial judge, the Court of Appeal concluded that the evidence did not demonstrate that Biaxin had the ability to cause neuropsychiatric side effects (general causation).19

Even if they are statistically very rare, the neuropsychiatric side effects reported in conjunction with the intake of Biaxin did trigger the manufacturer's disclosure obligation.20 However, the intensity of this obligation can be qualified as intermediary since no evidence shows that these rare serious side effects are caused by Biaxin.21

The Court of Appeal found that the manufacturer fulfilled its duty to warn by disclosing the possible neuropsychiatric side effects in the adverse effects section of the monograph. Under the state of the knowledge such disclosure constituted a sufficient warning about the possible risks.22 The manufacturer disclosed the information it possessed, considering the state of knowledge with respect to the medication.23 Thus, the monograph provided sufficient information to healthcare professionals about the benefits and risks of Biaxin. In turn, these professionals had to inform their patients in accordance with their specific conditions and based on their professional judgment.24 Finally, the information sheet which is generally provided along with Biaxin clearly explains how to access the information about less frequent side effects of the product.25


Many product liability class actions have been filed in Canada in the past twenty years against manufacturers of prescription drugs. While many such actions are currently pending before Canadian courts, this case is the first and only one so far in which a common issues trial was held and judgement on the merits of the case has been issued following the trial. The decision of the Court of Appeal in the Biaxin case could have a profound impact on future cases. One of the consequences of the Court's decision is that the punitive damages under the C.P.A. are not available to plaintiffs in product liability cases related to prescription drugs and collective recovery is less likely to be appropriate.


1 2019 QCCA 801 ("Court of Appeal").

2 2016 QCCS 5083 (Suzanne Hardy-Lemieux) ("Superior Court").

3 Court of Appeal, para. 66.

4 Court of Appeal, para. 169 et 172.

5 Court of Appeal, para. 159 et 160.

6 Court of Appeal, para. 17.

7 Court of Appeal, para. 57-59.

8 Court of Appeal, para. 61-64.

9 Court of Appeal, para. 65

10 Court of Appeal, para. 66.

11 In doing so, it confirmed the superior court's conclusion to that effect in : F. L. c. Astrazeneca Pharmaceuticals, p.l.c., 2010 QCCS 470, para. 83-90.

12 Court of Appeal, para. 67-70.

13 Court of Appeal, para. 89.

14 Court of Appeal, para. 91.

15 Court of Appeal, para. 119.

16 Court of Appeal, para. 163-169.

17 Court of Appeal, para. 138-142.

18 Court of Appeal, para. 159 et 160.

19 Court of Appeal, para. 198.

20 Court of Appeal, para. 206.

21 Court of Appeal, para. 215-216.

22 Court of Appeal, para. 246

23 Court of Appeal, para. 247.

24 Court of Appeal, para. 249.

25 Court of Appeal, para. 250-251.

To view the original article click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions